RNA, U6 small nuclear 618, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-618P profile across patient tissues and cancer cell-line models. RNU6-618P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RNU6-618P is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, RNU6-618P RNA expression shows 9,878 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, BRCA, and UVM as cancer lineages where RNU6-618P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-618P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-618P survival associations across molecular data types. RNU6-618P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-618P RNA expression–survival associations across cancer types. High RNU6-618P expression shows unfavorable associations in UCS, READ and PAAD, but favorable associations in HNSC, COAD and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify HNSC as the clearest survival context for RNU6-618P RNA expression.
This table summarizes RNU6-618P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-618P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-618P shows lower tumor expression in BRCA and THCA and higher tumor expression in STAD. The BRCA box plot shows higher RNU6-618P RNA expression in normal versus tumor tissue (log2 FC = −0.168, t-test p = .046).
This table shows molecular features associated with RNU6-618P in patient tissues and cancer cell lines. In patient samples, RNU6-618P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
